Publications by authors named "S Trudeau"
Introduction: Ursodeoxycholic acid (UDCA) slows disease progression among patients with primary biliary cholangitis (PBC), yet not all patients receive this standard-of-care medication. Our study aims to identify reasons why PBC patients did not receive the recommended UDCA treatment.
Methods: Using medical record data collected by the Fibrotic Liver Disease (FOLD) Consortium for 2006-2016, we identified PBC patients from a single site with no UDCA therapy record.
Evaluating the safety and efficacy of seladelpar for adults with primary biliary cholangitis.
Expert Opin Pharmacother
August 2024
Article Synopsis
- Seladelpar (MBX-8025) is a targeted PPAR-δ agonist currently being tested in Phase 3 trials for treating primary biliary cholangitis (PBC), with a once-daily dosage.
- The review discusses existing PBC treatments and highlights clinical trial results that show seladelpar's safety, effectiveness, and its positive impact on symptoms, including significant improvements in pruritus and overall quality of life.
- In trials, seladelpar met a key treatment benchmark in 61.7% of patients compared to 20% in the placebo group, indicating promising advancements for PBC therapy.
An Online Learning Experience Simulating Video Telehealth with Older Adults: Student Perceptions.
J Technol Behav Sci
December 2023
Older adults are an underserved population with a broad-spectrum of care needs due to multi-morbidity, including increasing rates of mental health conditions. Though a prime target for tele-behavioral health due to access barriers, older adults face a persistent digital divide that necessitates clinician training and education to ensure interprofessional tele-behavioral health is tailored to their needs. This paper presents findings from a simulation learning program designed to teach students about the role of video telehealth with populations with diverse needs.
View Article and Find Full Text PDFArticle Synopsis
- In 2019, a new liver allocation policy was implemented, shifting to a median model which aimed to improve simultaneous liver-kidney transplantation (SLKT) waitlist outcomes for patients with polycystic liver-kidney disease (PLKD).
- A study analyzing data from 317 patients between 2016 and 2021 found that the one-year transplant probability significantly increased from 37.9% before the policy change to 55.7% afterward, indicating better outcomes overall.
- The results showed that the policy effectively narrowed the gap in transplant probability between different transplant centers, particularly benefiting those with higher median Model for End-Stage Liver Disease (MMaT) scores.